Rufloxacin is a long-acting quinolone antibacterial agent with significant activity against both Gram-positive and Gram-negative bacteria, particularly Enterobacteriaceae. It exhibits high efficacy in the treatment of bacterial prostatitis and is well tolerated. It is used for urinary tract infections and lower respiratory tract infections caused by susceptible bacteria. Pseudomonas aeruginosa, Group D streptococci, and most anaerobic bacteria are resistant to this compound.